Toyama Chemical Begins US Phase I Clinical Trial for Neurotrophic Agent T-817MA for Alzheimer's Disease Treatment.Tokyo, Japan, July 21, 2005 - (JCNN JCNN Japan Corporate News Network ) - Toyama Chemical (TSE See Tokyo Stock Exchange. TSE 1. See Tokyo Stock Exchange (TSE). 2. See Toronto Stock Exchange (TSE). : 4518) announced on July 20 that it has launched in the US a Phase I clinical trail for T-817MA, a neurotrophic agent intended for the treatment of Alzheimer's disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia. . Specifically, the agent is expected to halt the progression of the disease by inhibiting nerve cell death and promoting neurite outgrowth. The company plans to start a US Phase II trial in the fourth quarter of 2006. Source: JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) http://www.japancorp.net Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion